Rexahn Pharmaceuticals, Inc.
OCUP US67577R1023
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -47% | -13% | -14% | -62% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Magrath George CEO |
0.98 USD |
100,000 Bought |
97,600 USD |
26/12/2024 | 26/12/2024 |
| Yerxa Benjamin R PR |
0.98 USD |
10,000 Bought |
9,834 USD |
21/11/2024 | 21/11/2024 |
| Magrath George CEO |
1.02 USD |
9,706 Bought |
9,943 USD |
15/11/2024 | 18/11/2024 |
| Magrath George CEO |
1.02 USD |
9,706 Bought |
9,943 USD |
15/11/2024 | 18/11/2024 |
| Magrath George CEO |
1.01 USD |
90,294 Bought |
91,215 USD |
15/11/2024 | 15/11/2024 |
| Magrath George CEO |
1.01 USD |
90,294 Bought |
91,215 USD |
15/11/2024 | 15/11/2024 |
| Jayagopal Ashwath SR OFF |
1.77 USD |
3,500 Bought |
6,178 USD |
22/05/2024 | 22/05/2024 |
| Magrath George CEO |
1.75 USD |
5,000 Bought |
8,773 USD |
17/05/2024 | 17/05/2024 |
| Schachle Joseph K COO |
2.05 USD |
2,000 Bought |
4,100 USD |
21/03/2024 | 21/03/2024 |
| Jhaveri Nirav S. CFO |
2.10 USD |
10,000 Bought |
21,000 USD |
21/03/2024 | 21/03/2024 |